Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomvastomig in advanced solid tumors
NCT03708328Phase 1Completed
- Sponsor
- Roche
- Start
- Oct 2018
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 6
01
Overview
Phase 1, open-label trial of lomvastomig in solid tumor, melanoma, non-small cell lung cancer (NSCLC) and 2 more (6 arms), sponsored by Roche. Primary endpoints: Number of Participants With a Dose-Limiting Toxicity, Number of Participants With at Least One AE by Highest Severity and 4 more. Started Oct 2018; status: completed.
02
Drugs
lomvastomig
03
Conditions
solid tumormelanomanon-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03708328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708328.